Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials.

Li DH, Whitmore JB, Guo W, Ji Y.

Clin Cancer Res. 2017 Jan 1;23(1):13-20. doi: 10.1158/1078-0432.CCR-16-1125. Epub 2016 Oct 14.

2.

Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy.

George DJ, Nabhan C, DeVries T, Whitmore JB, Gomella LG.

Cancer Immunol Res. 2015 Sep;3(9):1063-9. doi: 10.1158/2326-6066.CIR-15-0006. Epub 2015 May 5.

3.

Constraint on a varying proton-electron mass ratio 1.5 billion years after the big bang.

Bagdonaite J, Ubachs W, Murphy MT, Whitmore JB.

Phys Rev Lett. 2015 Feb 20;114(7):071301. Epub 2015 Feb 19.

PMID:
25763949
4.

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG.

Clin Cancer Res. 2015 Aug 15;21(16):3619-30. doi: 10.1158/1078-0432.CCR-14-2334. Epub 2015 Feb 3.

5.

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T.

Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):259-64. doi: 10.1038/pcan.2014.21. Epub 2014 Jun 24.

6.

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.

Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF.

Urology. 2013 Aug;82(2):410-5. doi: 10.1016/j.urology.2013.04.049.

PMID:
23896100
7.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.

Urology. 2013 Jun;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061. Epub 2013 Apr 9.

PMID:
23582482
8.

An analysis of leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer.

Flanigan RC, Polcari AJ, Shore ND, Price TH, Sims RB, Maher JC, Whitmore JB, Corman JM.

J Urol. 2013 Feb;189(2):521-6. doi: 10.1016/j.juro.2012.09.029. Epub 2012 Dec 14.

PMID:
23253957
9.

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.

Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL.

Cancer Immunol Immunother. 2013 Jan;62(1):137-47. doi: 10.1007/s00262-012-1317-2. Epub 2012 Aug 3.

10.

Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.

Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF.

J Natl Cancer Inst. 2012 Jul 18;104(14):1107-9; author reply 1109-12. doi: 10.1093/jnci/djs279. No abstract available.

PMID:
22825556
11.

Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer.

Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB.

J Urol. 2011 Sep;186(3):877-81. doi: 10.1016/j.juro.2011.04.070. Epub 2011 Jul 23.

PMID:
21788048
12.

Etanercept in adult patients with early onset ankylosing spondylitis.

Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A.

J Rheumatol. 2006 Aug;33(8):1634-6.

PMID:
16881118
13.

Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.

Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH; Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2006 Jun;54(6):1987-94.

14.

Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.

Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW.

J Rheumatol. 2006 May;33(5):854-61. Epub 2006 Mar 15.

PMID:
16541481
15.

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.

Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.

Curr Med Res Opin. 2006 Jan;22(1):169-83.

PMID:
16393443
16.

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis.

Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, Tsuji WH, Leff JA.

J Rheumatol. 2005 Jul;32(7):1232-42.

PMID:
15996057
17.

Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.

Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB.

J Rheumatol. 2004 Aug;31(8):1532-7.

PMID:
15290731
18.

Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.

Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB.

J Rheumatol. 2004 Jul;31(7):1356-61.

PMID:
15229957
19.

Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation.

Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, Sherman SA, Taylor SM, Sanderson SD.

Int Immunopharmacol. 2001 Nov;1(12):2151-62.

PMID:
11710544
20.

Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.

Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM; IL-4R Asthma Study Group.

J Allergy Clin Immunol. 2001 Jun;107(6):963-70.

PMID:
11398072
21.

A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS.

Brites C, Gilbert MJ, Pedral-Sampaio D, Bahia F, Pedroso C, Alcantara AP, Sasaki MD, Matos J, Renjifo B, Essex M, Whitmore JB, Agosti JM, Badaro R.

J Infect Dis. 2000 Nov;182(5):1531-5. Epub 2000 Oct 9.

PMID:
11023477
22.

Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.

Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, Gilbert MJ, Deresinski S.

AIDS. 2000 Mar 10;14(4):387-95.

PMID:
10770541
23.

Pharmacological characterization of antagonists of the C5a receptor.

Paczkowski NJ, Finch AM, Whitmore JB, Short AJ, Wong AK, Monk PN, Cain SA, Fairlie DP, Taylor SM.

Br J Pharmacol. 1999 Dec;128(7):1461-6.

24.

Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L.

Am J Respir Crit Care Med. 1999 Dec;160(6):1816-23.

PMID:
10588591
25.

Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.

Whitmore JB, Kris MG, Hesketh PJ, Grote TH, DuBois DM, Cramer MB, Hahne WF.

Support Care Cancer. 1998 Sep;6(5):473-8.

PMID:
9773466
26.

Supplemental Content

Loading ...
Support Center